Randomized, Open-Label, Phase 3 Study Of Subcutaneous Daratumumab (Dara Sc) Versus Active Monitoring In Patients (Pts) With High-Risk Smoldering Multiple Myeloma (Smm): Aquila.
JOURNAL OF CLINICAL ONCOLOGY(2018)
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要